These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29236325)

  • 1. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
    Tian Y; Wang G; Hu Q; Xiao X; Chen S
    J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
    Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
    Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
    Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
    BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
    Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of a small core transcriptional circuit regulated by AML1-ETO.
    Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
    Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.
    Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J
    J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
    Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
    Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genomic distribution of AML1-ETO fusion protein binding sites].
    He MM; Shi JT; Zhu XH; Jin W; Wang P; Zhang J; Wagn KK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):553-8. PubMed ID: 20561400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
    Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
    Dou L; Yan F; Pang J; Zheng D; Li D; Gao L; Wang L; Xu Y; Shi J; Wang Q; Zhou L; Shen N; Singh P; Wang L; Li Y; Gao Y; Liu T; Chen C; Al-Kali A; Litzow MR; Chi YI; Bode AM; Liu C; Huang H; Liu D; Marcucci G; Liu S; Yu L
    Nat Commun; 2019 Nov; 10(1):5051. PubMed ID: 31699991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
    Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
    Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.